Ian Bezek

Ian Bezek

Ian Bezek earned his economics degree from Colorado State University in 2010. He then worked as an analyst for Kerrisdale Capital, a New York City-based activist hedge fund, from 2011-13. Since then, Ian has focused on finding under-the-radar investment opportunities, particularly overseas. To that end, he taught himself Spanish and has lived in Mexico and Argentina among other countries. He currently resides in Colombia with his family.

You can interact with Ian on Twitter.

Recent Articles

Down 75% From the High, AI Stock is a Strong Buy

The pandemic did a number on C3.ai's revenue growth prospects. But as the economy reopens, look for AI stock to get back on track this fall.

7 High-Risk Stocks To Sell Before You Get Burned

The market is clearly dividing between winners and losers this summer. These seven stocks to sell could face a rough fall ahead.

Viacom Stock: It’s Time to Assess the Pros and Cons

If Viacom can manage a successful transition into the streaming future, VIAC stock should have upside. But that could be quite the challenge.

AT&T’s Upcoming Discovery Deal Is Its Only Appeal

After an acquisition binge, AT&T is trying to undo many of its recent transactions. This process will be rough for T stock shareholders.

7 Infrastructure Stocks to Buy Before They Get a Biden Bill Boost

Infrastructure stocks are set for a boom as $1 trillion of money hits the sector. Here are seven to have on your radar today.

ABNB Stock Hasn’t Moved Much yet, but It’s on the Verge After Earnings

ABNB stock should be able to recover some of its recent losses following this earnings report as the world economy reopens.

Finally, It’s Time To Buy Baidu Stock

Baidu has underperformed its Chinese internet peers for many years now. However, BIDU stock is now poised to deliver superior returns.

Surging Jobs Number Reinforces the Bull Case for Wells Fargo Stock

Wells Fargo's turnaround is in full bloom. This past week's employment data further highlights the upside for WFC stock going forward.

Even at Current Lows, QuantumScape Stock Still Offers No Reason To Buy

QS stock plunged after a brutal investigative report earlier this year. Management's inability to deflect these concerns makes QuantumScape a risky investment.

Analyzing the Potential Risks of Cassava Sciences

Cassava Sciences has a promising drug candidate for Alzheimer's. However, SAVA stock may be overpriced based on the limited data so far.